Literature DB >> 11679425

Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats.

J S Harmon1, C E Gleason, Y Tanaka, V Poitout, R P Robertson.   

Abstract

Type 2 diabetes is caused by a combination of beta-cell dysfunction and insulin resistance. Over time, hyperglycemia worsens, a phenomenon that has been attributed to deleterious effects of chronic hyperglycemia (glucotoxicity) or chronic hyperlipidemia (lipotoxicity) on beta-cell function and is often accompanied by increased islet triacylglycerol (TAG) content and decreased insulin gene expression. To examine these two potentially pathogenic forces, we studied Zucker rats (leptin receptor wild type, +/+; heterozygous, +/-; and mutant, -/-). First, +/+ and +/- Zucker rats were compared metabolically. At 6 weeks of age, the +/- rats had a lower level of islet insulin mRNA compared with +/+. At 12 weeks of age, differences were found in body weight and islet TAG content; however, levels of insulin mRNA were equivalent. Second, we examined whether worsening of the diabetic state in the homozygous mutant (-/-) Zucker diabetic fatty (ZDF) rat is related more to chronic hyperglycemia or to hyperlipidemia. The ZDF rats were treated for 6 weeks with either bezafibrate, a lipid-lowering drug that does not affect plasma glucose levels, or phlorizin, a drug that reduces plasma glucose without lowering lipid levels. Bezafibrate treatment lessened the rise in plasma TAG observed in nontreated rats (239 +/- 16 vs. 388 +/- 36 mg/dl, treated versus nontreated; P < 0.0001) but did not prevent the rise in fasting plasma glucose. Despite lowering plasma TAG, bezafibrate was not effective in preventing an increased islet TAG content and did not prevent the associated decrease in insulin mRNA levels. Phlorizin treatment prevented hyperglycemia (61 +/- 2 vs. 145 +/- 7 mg/dl, treated versus nontreated; P < 0.0001) and lowered islet TAG content (32.7 +/- 0.7 vs. 47.8 +/- 2.7 ng/islet, treated versus nontreated; P < 0.0001) and preserved insulin mRNA levels without preventing hypertriglyceridemia. Plasma free fatty acid level did not correlate with changes in islet TAG or insulin mRNA levels. We conclude that antecedent elevated plasma glucose levels, not plasma lipid levels, are associated with elevated islet TAG content and decreased insulin mRNA levels in ZDF animals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679425     DOI: 10.2337/diabetes.50.11.2481

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  33 in total

Review 1.  Islet beta cell failure in type 2 diabetes.

Authors:  Marc Prentki; Christopher J Nolan
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 2.  Glucolipotoxicity: fuel excess and beta-cell dysfunction.

Authors:  Vincent Poitout; R Paul Robertson
Journal:  Endocr Rev       Date:  2007-11-29       Impact factor: 19.871

3.  The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.

Authors:  Lucy C Pickavance; Christian L Brand; Karsten Wassermann; John P H Wilding
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

4.  Nrf2/antioxidant pathway mediates β cell self-repair after damage by high-fat diet-induced oxidative stress.

Authors:  Tsehay Abebe; Jana Mahadevan; Lindsey Bogachus; Stephanie Hahn; Michele Black; Elizabeth Oseid; Fumihiko Urano; Vincenzo Cirulli; R Paul Robertson
Journal:  JCI Insight       Date:  2017-12-21

Review 5.  Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.

Authors:  Surapon Tangvarasittichai
Journal:  World J Diabetes       Date:  2015-04-15

6.  Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

Authors:  Atsuo Tahara; Eiji Kurosaki; Masanori Yokono; Daisuke Yamajuku; Rumi Kihara; Yuka Hayashizaki; Toshiyuki Takasu; Masakazu Imamura; Li Qun; Hiroshi Tomiyama; Yoshinori Kobayashi; Atsushi Noda; Masao Sasamata; Masayuki Shibasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-03       Impact factor: 3.000

7.  Reduced hippocampal cell differentiation in the subgranular zone of the dentate gyrus in a rat model of type II diabetes.

Authors:  In Koo Hwang; Sun Shin Yi; Yo Na Kim; Il Yong Kim; In Se Lee; Yeo Sung Yoon; Je Kyung Seong
Journal:  Neurochem Res       Date:  2007-08-22       Impact factor: 3.996

8.  Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition.

Authors:  X Yu; S McCorkle; M Wang; Y Lee; J Li; A K Saha; R H Unger; N B Ruderman
Journal:  Diabetologia       Date:  2004-12-02       Impact factor: 10.122

9.  Stevioside Counteracts Beta-Cell Lipotoxicity without Affecting Acetyl CoA Carboxylase.

Authors:  Jianguo Chen; Per Bendix Jeppesen; Iver Nordentoft; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2007-02-10

Review 10.  Glucolipotoxicity of the pancreatic beta cell.

Authors:  Vincent Poitout; Julie Amyot; Meriem Semache; Bader Zarrouki; Derek Hagman; Ghislaine Fontés
Journal:  Biochim Biophys Acta       Date:  2009-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.